 |
인쇄하기
취소
|
Hanmi Pharm, DKSH sign deal to sell three incrementally modified drugs
Hanmi Pharmaceuticals Co. said Wednesday it established a strategic partnership with DKSH, the leading Market Expansion Services Group with a focus on Asia.
Under the exclusive distribution agreement, DKSH will market Hanmi’s three incrementally modified drugs (IMDs) over the next ten years: Amosartan (amlodipine camsylate/losartan potassium), Esomezol (esomeprazole strontium) and Pidogul (c...
Under the exclusive distribution agreement, DKSH will market Hanmi’s three incrementally modified drugs (IMDs) over the next ten years: Amosartan (amlodipine camsylate/losartan potassium), Esomezol (esomeprazole strontium) and Pidogul (c...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.